https://bioutah.org/nomi-health-ceo-mark-newman-testifies-before-u-s-house-on-direct-contracting/2026-07-01T23:21:22ZBioUtahenNomi Health CEO Mark Newman Testifies Before U.S. House on Direct Contracting2026-07-01T23:21:22ZBloghttps://bioutah.org/co-diagnostics-completes-clinical-and-analytical-studies-in-preparation-for-fda-510k-submission-of-upper-respiratory-point-of-care-test/2026-07-01T23:18:11ZBioUtahenCo-Diagnostics Completes Clinical and Analytical Studies in Preparation for FDA 510(k) Submission of Upper Respiratory Point-of-Care Test2026-07-01T23:18:11ZBloghttps://bioutah.org/cytiva-completes-doubling-of-utah-sites-liquid-media-production-capacity/2026-07-01T22:50:38ZBioUtahenCytiva Completes Doubling of Utah Site’s Liquid Media Production Capacity2026-07-01T22:50:38ZBloghttps://bioutah.org/biomerieux-seeks-fda-clearance-for-updated-gastrointestinal-testing-panels/2026-07-01T21:18:56ZBioUtahenbioMérieux Seeks FDA Clearance for Updated Gastrointestinal Testing Panels2026-07-01T21:18:56ZBloghttps://bioutah.org/m42s-iros-launches-uaes-first-genomics-driven-clinical-trial-to-prevent-alzheimers-disease/2026-07-01T21:14:33ZBioUtahenM42’s IROS launches UAE’s first genomics-driven clinical trial to prevent Alzheimer’s disease2026-07-01T21:14:06ZBloghttps://bioutah.org/ratio-therapeutics-enters-strategic-actinium-225-supply-agreement-with-pantera-to-support-radiopharmaceutical-development-programs/2026-07-01T21:12:05ZBioUtahenRatio Therapeutics Enters Strategic Actinium-225 Supply Agreement with PanTera to Support Radiopharmaceutical Development Programs2026-07-01T21:12:05ZBloghttps://bioutah.org/polaritybio-announces-submission-of-its-biologics-license-application-for-skinte-for-the-treatment-of-wagner-grade-1-diabetic-foot-ulcers/2026-07-01T21:10:22ZBioUtahenPolarityBio Announces Submission of its Biologics License Application for SkinTE® for the Treatment of Wagner Grade 1 Diabetic Foot Ulcers2026-07-01T21:10:22ZBloghttps://bioutah.org/kidneyintelx-delivers-unprecedented-two-year-real-world-outcomes-in-diabetic-kidney-disease-no-comparable-risk-assessment-tool-exists/2026-07-01T21:09:15ZBioUtahenKidneyIntelX® Delivers Unprecedented Two-Year Real-World Outcomes in Diabetic Kidney Disease: No Comparable Risk Assessment Tool Exists2026-07-01T21:09:15ZBloghttps://bioutah.org/fda-approves-roflumilast-cream-0-3-for-plaque-psoriasis-down-to-age-2/2026-07-01T20:35:05ZBioUtahenFDA Approves Roflumilast Cream 0.3% for Plaque Psoriasis Down to Age 22026-07-01T20:34:36ZBloghttps://bioutah.org/arcutis-launches-new-virtual-health-platform-supporting-access-to-care-for-individuals-living-with-chronic-inflammatory-skin-diseases-including-approved-zoryve-roflumilast-indications/2026-07-01T20:33:18ZBioUtahenArcutis Launches New Virtual Health Platform Supporting Access to Care for Individuals Living with Chronic Inflammatory Skin Diseases, Including Approved ZORYVE® (roflumilast) Indications2026-07-01T20:31:20ZBloghttps://bioutah.org/early-phase-data-support-novel-contrast-agent/2026-07-01T20:20:05ZBioUtahenEarly-Phase Data Support Novel Contrast Agent2026-07-01T20:19:20ZBloghttps://bioutah.org/biomerieux-seeks-fda-authorization-for-point-of-care-vaginitis-test/2026-07-01T20:17:42ZBioUtahenbioMérieux Seeks FDA Authorization for Point-of-Care Vaginitis Test2026-07-01T20:17:42ZBloghttps://bioutah.org/nusano-completes-major-milestone-toward-commercial-radioisotope-production/2026-07-01T20:16:08ZBioUtahenNUSANO COMPLETES MAJOR MILESTONE TOWARD COMMERCIAL RADIOISOTOPE PRODUCTION2026-07-01T20:16:08ZBlog